Medical Marijuana in Canada: A Growth Industry

US Biopharma In-Licenses 3 New Assets
Source: Dr. Martin Fan (10/24/2025)

Zenas BioPharma Inc.'s (ZBIO:NASDAQ) target price is increased 14% to reflect the Phase 3 investigative multiple sclerosis drug included in this recent deal, noted a Wedbush report.

read more >

Chen's High-Grade Gold, Silver Plays for Q4
Source: Streetwise Reports (10/23/2025)

It has been quite a year for precious metals such as gold and silver, and Chen Lin's top stock picks for the quarter bear that out. Which companies have the most upside?

read more >

AI Cancer Discovery Shows Breakthrough in Brain-Targeting Treatment
Source: Streetwise Reports (10/20/2025)

Rakovina Therapeutics Inc. (RKV:TSX.V) is set to unveil new preclinical data from its AI-driven ATR inhibitor program at a major international cancer conference in Boston. The findings highlight strong efficacy and blood-brain barrier permeability, a potential breakthrough for hard-to-treat tumors and brain metastases.

read more >

Biopharma's New MASH Drug Has Two MOAs
Source: Patrick Trucchio (10/15/2025)

Altimmune Inc.'s (ALT:NASDAQ) pemvidutide achieves metabolic improvement and directs hepatic anti-fibrotic activity with singular dosing, noted an H.C. Wainwright & Co. report.

read more >

Therapeutics Company Advances Gene Therapy Breakthrough
Source: Mitchell Kapoor and Dr. Raghuram Selvaraju (10/09/2025)

In an updated research note on October 7, H.C. Wainwright & Co. analysts Mitchell Kapoor and Dr. Raghuram Selvaraju note significant risk reduction for Lexeo Therapeutics Inc. (LXEO:NASDAQ) as formal alignment with the FDA makes its new drug increasingly likely to gain approval.

read more >